Slide 1: Commercialising the next generation non-invasive cardiac monitoring technology
For personal use only Commercialising the next generation non-invasive cardiac monitoring technology Robert Phillips MPhil(med), FASE, DMU(cardiol) Chief Executive Officer May 2012
Slide 2: Our goal
Our goal For personal use only Uscom’s mission is to create long-term shareholder value by transforming and improving cardiac output monitoring and making USCOM the standard of clinical care worldwide 2 The measure of life www.uscom.com.au
Slide 3: Agenda today
Agenda today For personal use only • Who we are • What we do and why our product is needed • Current market and the future potential • Our strategy to create value • Next steps • Background on the market and new product pipeline 3 The measure of life www.uscom.com.au
Slide 4: Uscom corporate overview
Uscom (ASX: UCM) corporate overview For personal use only • We are transforming and improving the practice of cardiac monitoring • Main product is Ultra-Sound Cardiac Output Monitor (USCOM) • US FDA cleared, CE marking for Europe and rest of world • Revenues of approximately $1.0 million and growing
Slide 5: Selected financial snapshot 1H2012
Selected financial snapshot 1H2012 For personal use only • ASX code: UCM Summary of 5-year annual revenues • Listed: 2003 • Market cap: $5 million $’000 • Stock on issue: 52 million 1,800 • 52 week high/low $0.24-$0.07 • 1H2012 product sales: $0.5 million • Cash @ 31 Dec ‘11: $1.0 million 1,400 • To
Slide 6: How it works...
How it works... For personal use only “The most accurate clinical method of measuring cardiac output” Cardiac output Non-invasive Cardiac index Compact Stroke volume Intuitive Stroke volume index Heart rate Peak velocity Measures left and right heart Software works with all touch Real time screen un
Slide 7: What it does now...
What it does now... For personal use only • Monitors the heart noninvasively using patented ultra-sound • Safe, painless, non-invasive method to measure how well the heart is functioning – a key measure for most hospital patients • Allows quick and very accurate cardiac assessment • Uses state-of–th
Slide 8: What it can also do…
What it can also do… For personal use only Current markets: • Paediatrics • Critical care • Emergency • Anesthesia Future new market applications: • Heart failure and hypertension • Heart transplantation • Liver transplantation • Drug research • Emergency Response, Military • Electrophysiology (pace
Slide 9: Global needs driving future demand
Global needs driving future demand For personal use only 1. Invasive methods are inaccurate and ineffective 2. Need to reduce risk of infection 3. Need to improve levels of care 4. Need to reduce costs 9 The measure of life www.uscom.com.au
Slide 10: A business with multiple opportunities…
A business with multiple opportunities… For personal use only In hospital market (current) • Pediatric ICU and neonatal ICU, Adult ICU and ED, Anesthesia monitoring Un-partnered new markets • Hypertension, Heart failure, Nurse led CO measurement, Dialysis, ED trauma resuscitation, Liver transplantat
Slide 11: …and a clear competitive advantage
…and a clear competitive advantage For personal use only Non‐ SV beat Method Man. Technology Rel+Rep invasive Simple Cost Portable to beat USCOM 1A Uscom Doppler ✓ ✓ ✓ ✓ ✓ ✓ BioZ Sonosite BioImpedance ✗ ✓ ✓ ✗ ✓ ✗ NiCOM Cheetah BioReactance ✗ ✓ ✓ ✗ ✓ ✗ Nexfin Bmeye APP ✗ ✓ ✓ ✓ ✓ ✗ CardioQ Deltex Dopp
Slide 12: Commercial achievements to date
Commercial achievements to date For personal use only Product validated • Independently validated as safe and effective • Manufacturing and distribute • Growing KOL interest and support worldwide • Established global brand protected by extensive long-term IP estate Regulatory approvals worldwide • A
Slide 13: Regional product sales growth 1H2012
Regional product sales growth 1H2012 For personal use only A total of 500 units currently in use worldwide Units Asia US Europe Sold Pacific 45 % 5% 2011 50 % 13
Slide 14: Regional sales revenues FY2011
Regional sales revenues FY2011 For personal use only x $100,000 Asia Pacific United States Europe, Africa & Mid East 12 12 12 10 10 10 8 8 8 6 6 6 4 4 4 2 2 2 0 0 0 2010 2009 2010 2008 2009 2007 2008 2011 2007 2011 2010 2009 2008 2007 2011 14 The measure of life www.uscom.com.au
Slide 15: Short term growth – expand current markets
Short term growth – expand current markets For personal use only Europe • Recently added to UK’s NHS Technology Adaptation Centre guidelines • Program to ensure USCOM included in all EU treatment guidelines USA • Working with established distributor to engage new customers/KOLs • Lost momentum post-
Slide 16: Long term growth – new products
Long term growth – new products For personal use only • Invested total of $20 million to date to develop the technology • New products are catalyst for long term growth and shareholder value • Several new technologies moving closer to the clinic • Each has own significant global market potential • F
Slide 17: Long term growth – clinical evidence
Long term growth – clinical evidence For personal use only • Sales and revenues will grow with awareness and acceptance • 253 papers and peer reviewed articles across multiple disciplines • Growing body of positive independent clinical evidence • Evidence and outcomes data coordinated with sales and
Slide 18: Results focused strategy to create value
Results focused strategy to create value For personal use only • Practice changing research has established USCOM as the new clinical gold standard cardiac monitor – this can be converted to sales • EU and US Government practice recommendations – UK NHS intra- operative fluid optimisation recommenda
Slide 19: Results focused strategy to create value
Results focused strategy to create value For personal use only We are milestone-driven and outcomes focused Sell or license Execute major multiple new global products licensing, based on Rapidly grow partnership or current sales revenues distribution proven by using new deals for the platform clinic
Slide 20: 2012 capital raising
2012 capital raising For personal use only • Uscom is currently preparing for a capital raising in 2012 • Capital raised will be prudently used to: • Grow sales team and revenues with focus on key markets • Expedite business development • Global partnering and licensing negotiations underway • Expan
Slide 21: Summary
Summary For personal use only • Commercially focused Sydney-based ASX-listed medical device company focused on non-invasive cardiac monitoring technology • Revenue generating global business ($1million in 2011 and growing) • World-leading, ‘practice changing’ medical technology poised to transform c
Slide 22: Thank you
USCOM For personal use only Thank you Rob Phillips Chief Executive Officer T: +61 418681154 E: rob@uscom.com.au 22 The measure of life www.uscom.com.au
Slide 23: Appendicies
For personal use only Appendicies
Slide 24: Product pipeline adds potential value
Product pipeline adds potential value For personal use only Current product line • Patent protected USCOM technology – 2021+ • USCOM 1A – Advanced haemodynamics • OXYCOM – Real time Oxygen Delivery (DO2) • USCOMt – Haemodynamics transducer • CARECOM – Physiology mapping and treatment guide • EDUCOM
Slide 25: Who says there is a need for Uscom?
Who says there is a need for Uscom? For personal use only “Non-invasive hemodynamic monitoring is the number one unmet need...” Survey of 700 physicians and nurses worldwide, by GE Medical Systems . 25 The measure of life www.uscom.com.au
Slide 26: The emerging gold standard of clinical care
The emerging gold standard of clinical care For personal use only Home of Jeremy Swan and William Ganz and the PAC! Question: Is there still a place for the Pulmonary Artery Catheter in the ICU Practice? ANSWER: “USCOM may safely replace the PAC in many clinical applications” Source: Jain S, Allins
Slide 27: The emerging gold standard of clinical care
The emerging gold standard of clinical care For personal use only • Fluid − “The change in SV with PLR was the only haemodynamic index with significant predictive ability” 91% +ve predictive value. Critical Care 2009;13:R111 • Inotropes/Vaso’s − “USCOM was 6 to 8 times as sensitive to changes in CO
Slide 28: Cardiac monitoring market landscape
Cardiac monitoring market landscape For personal use only Clinical assessment – BP, HR, colour, reperfusion time etc. Inaccurate Non-invasive • USCOM – Transcutaneous CW Doppler - safe, accurate, effective • ICG – Bio-impedance (inaccurate) – questionable accuracy and unproven • Tonometry – Transcut
Slide 29: Cardiac monitoring market landscape
Cardiac monitoring market landscape For personal use only Capitalised value of USCOM and current competitors, $ million • Last capital raising $0.30 • Current price $0.09 • Equivalent price to competitors $1.20 29 The measure of life www.uscom.com.au
Slide 30: Potential value of product pipeline
Potential value of product pipeline For personal use only Worldwide market Cap value at 25% estimate penetration, 50% Department Total beds* (USA) ($15k,1/10beds) profit and x20PE Neonatal ICU 17,000 $51m $128m Paediatric ICU 4,000 $12m $30m Cardiac Surgery 10,000 $30m $75m Adult ICU 50,000 $150m $3
Slide 31: Potential value of product pipeline
Potential value of product pipeline For personal use only License Gold Standard CO monitoring Crit Care Monitoring module Ultrasound CO module $500m = 20% of 250k x$10kpa $500m = 20% of 250k x $10kpa Ultrasound CO module Home care Hypertension, HF and sleep monitoring ? Anesthesia CO module $240 = 2
Slide 32: Potential value of product pipeline
Potential value of product pipeline For personal use only USCOM USCOM Current Sales at 4yrs 20% 50% Profit USCOM – sales 1m 400 ($15k) $6m $6m $3m USCOM – new 0 400 ($15k) $6m $6m $3m USCOM – monitors 0 250,000 ($10k) $50m $25m $20m USCOM – ultrasound 0 250,000 ($10k) $50m $25m $20m USCOM – ventilat
Slide 33: Potential value of product pipeline
Potential value of product pipeline For personal use only Uscom sales potential and goals $million • Partnership with instant take up of technology • 4 new markets • 20% Penetration • No Upgrades • USCOM gross $84m pa • Cap val = 12xPE = $1,008m • 100m shares @ $18 33 The measure of life www.uscom.c
Slide 34: Extensive intellectual property estate
Extensive intellectual property estate For personal use only USCOM has significant value in its core patent • Ultrasound is the emerging diagnostic modality – The USCOM patent is all Doppler Ultrasound cardiac output monitoring. 34 The measure of life www.uscom.com.au
Slide 35: Extensive intellectual property estate
Extensive intellectual property estate For personal use only USCOM has significant value in its extensive IP estate • 23 granted patents • 13 different applications • 2 registered trade marks 35 The measure of life www.uscom.com.au
Slide 36: A growing body of independent evidence
A growing body of independent evidence For personal use only 250+ Peer reviewed publications and presentations Emergency, Pediatrics, Cardiac transplantation, Electrophysiology, Heart Failure, Emergency transport, Anesthesia, Liver transplantation, ICU, Septic shock, Pre- eclampsia, Pulmonary hypert
Slide 37: Testimonials
Testimonials For personal use only “This machine is saving lives, there are no two ways about it.” Professor Brendan Smith, Anesthetist, Intensivist and Emergency Physician, N.S.W. Dept of Health, Australia “The USCOM device is a simple method of accurately and noninvasively measuring central circul